Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

NCT06361238 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can help prevent delirium in older adults with diabetes after they undergo heart surgery.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 260 people Planned (estimated).

Who can join Ages 60+ · all sexes

Timeline Started 2024-11 · est. completion 2028-03

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06361238 ↗

Description as written by the study sponsor.

This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.

Treatments tested

Liraglutide injection also known as Victoza Drug

Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
Placebo injection also known as Normal saline Drug

Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.

Main thing measured	The incidence of delirium
Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions studied	Delirium, Postoperative
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06361238 ↗